Zura Bio Ltd financial data

Symbol
ZURA, ZURAW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4225 Executive Square, Suite 600, La Jolla, California
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
JATT Acquisition Corp (to 3/21/2023)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 569 % +170%
Debt-to-equity 31.1 %
Return On Equity -90.5 % -112%
Return On Assets -57.2 % -9.54%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.6 M shares +748%
Common Stock, Shares, Outstanding 43.6 M shares +61.1%
Entity Public Float 357 M USD +160%
Common Stock, Value, Issued 4 K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 46.9 M shares +1221%
Weighted Average Number of Shares Outstanding, Diluted 46.9 M shares +1221%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 42.7 M USD +103%
General and Administrative Expense 20.6 M USD +328%
Operating Income (Loss) -63.3 M USD -534%
Nonoperating Income (Expense) 632 K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -58.5 M USD -99.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -58.5 M USD -35.8%
Earnings Per Share, Basic 0.65 USD/shares -100%
Earnings Per Share, Diluted 0.65 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 99.8 M USD +723875%
Assets, Current 90.5 M USD +104%
Property, Plant and Equipment, Net 9 K USD
Assets 90.5 M USD +104%
Accounts Payable, Current 1.49 M USD -38.4%
Liabilities, Current 14.7 M USD +194%
Liabilities 16.3 M USD +149%
Retained Earnings (Accumulated Deficit) -111 M USD -166%
Stockholders' Equity Attributable to Parent 61 M USD +119%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 62.6 M USD +125%
Liabilities and Equity 90.5 M USD +104%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.98 M USD -53%
Net Cash Provided by (Used in) Financing Activities 121 M USD +34010%
Net Cash Provided by (Used in) Investing Activities -5.01 M USD
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 43.6 M shares +61.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 89.8 M USD +104%
Deferred Tax Assets, Valuation Allowance 17.9 M USD +179%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 17.9 M USD +179%
Payments to Acquire Property, Plant, and Equipment 7 K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.95 M USD +431%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1 M shares 0%
Additional Paid in Capital 172 M USD +147%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 9.7 M USD +1.82%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%